StockNews.AI
AKBA
StockNews.AI
166 days

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

1. Akebia will report Q4 and FY 2024 results on March 13, 2025. 2. A conference call will discuss financial results and business highlights. 3. Investors can access the call via registration and webcast. 4. Akebia focuses on improving the lives of patients with kidney disease.

Earnings
+4.04%Current Return
VS
-1.35%S&P 500
$1.85503/06 08:21 AM EDTEvent Start
$1.9303/07 02:49 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Earnings reports can influence stock prices; results may vary based on performance.

How important is it?

The earnings call is significant but still depends on actual results.

Why Short Term?

Immediate stock price response expected post-results; historical volatility common.

Related Companies

AKBA
Akebia to Host Conference Call on March 13, 2025, at 8:00 a.m. ET March 06, 2025 08:00 ET  | Source: Akebia Therapeutics, Inc. CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 13, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, March 13, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.  A live webcast of the conference call will be available via the Investors section of Akebia’s website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia’s website at http://ir.akebia.com. About Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release. Akebia Therapeutics ContactMercedes Carrascomcarrasco@akebia.com

Related News